Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas…
CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening
Medicare coverage will provide approximately 65 million eligible Medicare beneficiaries access to the first FDA-approved colon cancer screening…
Geneoscopy's ColoSense® Test Included as a Preferred Option in the American Cancer Society Colorectal Cancer Screening Guidelines Update
Guideline inclusion recognizes ColoSense as an evidence-based, preferred solution for colorectal cancer screening in average-risk individuals aged…
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent
Decision removes last patent hurdle as Geneoscopy advances ColoSense®, its RNA-based noninvasive colorectal cancer screening test ST. LOUIS, Mo. –…
Geneoscopy’s Scrape-Free Collection Method for Colorectal Cancer Screening Validated by New Data and Peer-Reviewed Publication
ST. LOUIS, Mo.—October 22, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
ST. LOUIS, Mo.—August 22, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
Pairing diagnostic innovation with improved patient experience, ColoSense aims to streamline the screening process and increase compliance ST. LOUIS,…
Geneoscopy to Participate in Upcoming Investor Conferences
ST. LOUIS, Mo.—July 17, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences’ ’781 Patent
Decision removes key patent hurdle as Geneoscopy advances ColoSense, its RNA-based noninvasive colorectal cancer screening test ST. LOUIS, Mo.—July…
